We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus (HTN2DM)

This study is currently recruiting participants.
Verified March 2016 by Kin Lam TSUI, Pamela Youde Nethersole Eastern Hospital
Sponsor:
ClinicalTrials.gov Identifier:
NCT01887067
First Posted: June 26, 2013
Last Update Posted: March 30, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Kin Lam TSUI, Pamela Youde Nethersole Eastern Hospital
  Purpose
To demonstrate the efficacy of renal denervation therapy in treating resistant hypertension and its effect on glucose metabolism in patients with type 2 diabetes mellitus

Condition Intervention
Hypertension, Resistant Diabetes Mellitus Renal Denervation Therapy Procedure: Renal denervation therapy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus

Further study details as provided by Kin Lam TSUI, Pamela Youde Nethersole Eastern Hospital:

Primary Outcome Measures:
  • Change in office systolic & diastolic blood pressure from baseline to 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Change in office systolic and diastolic blood pressure up to 3 years [ Time Frame: 3 years ]
  • Change in insulin sensitivity [ Time Frame: 12 months ]
    HOMA-IR index at baseline, 3-month and 12-month

  • Change in glucose metabolism [ Time Frame: 3 years ]

Estimated Enrollment: 15
Study Start Date: June 2013
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Renal denervation therapy Procedure: Renal denervation therapy
Other Name: Renal denervation using Symplicity® Catheter System™

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ranges from 18 to 70 years inclusive
  • Essential hypertension
  • Office Systolic BP (SBP) ≥ 150 mmHg or Diastolic BP (DBP) ≥ 90mmHg
  • 3 or more anti-hypertensive medications of different classes, including a diuretic, or documented intolerance to multiple medications
  • Type 2 Diabetes Mellitus on oral hypoglycaemic agent (OHA)
  • 2 functional kidneys; eGFR ≥ 45 mL/min/1.73m² (MDRD formula)
  • Suitable renal anatomy compatible with the endovascular denervation procedure

Exclusion Criteria:

  • Individual has renal artery anatomy that is ineligible for treatment including:
  • Patients with secondary hypertension
  • Myocardial infarction, unstable angina pectoris, cerebrovascular accident within 6 months
  • Patient with type 1 diabetes mellitus
  • Patient on insulin due to oral drug failure
  • Renovascular abnormalities (including severe renal artery stenosis, previous renal stenting or angioplasty, or known dual renal arteries)
  • Pregnancy
  • Patient with any implantable device incompatible with radiofrequency energy delivery
  • Hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous
  • Any serious medical condition, which in the opinion of the investigator, may limit the life expectancy of patients or adversely
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01887067


Contacts
Contact: Kin Lam Tsui, FRCP (Edin, Glasg) +852 25956412 tsuikl1@ha.org.hk

Locations
Hong Kong
Pamela Youde Nethersole Eastern Hospital Recruiting
Hong Kong, Hong Kong
Contact: Kin Lam Tsui, FRCP (Edin, Glasg)    +852 25956412    tsuikl1@ha.org.hk   
Sponsors and Collaborators
Pamela Youde Nethersole Eastern Hospital
Investigators
Principal Investigator: Kin Lam Tsui, FRCP (Edin, Glasg) Pamela Youde Nethersole Eastern Hospital
  More Information

Responsible Party: Kin Lam TSUI, Consultant Physician, Pamela Youde Nethersole Eastern Hospital
ClinicalTrials.gov Identifier: NCT01887067     History of Changes
Other Study ID Numbers: HKEC-2012-038
First Submitted: June 24, 2013
First Posted: June 26, 2013
Last Update Posted: March 30, 2016
Last Verified: March 2016

Keywords provided by Kin Lam TSUI, Pamela Youde Nethersole Eastern Hospital:
Hypertension
Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Hypertension
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases